1. Scrip
  2. >>R&D

First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

 
• By Mandy Jackson

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Evening scene asphalt international race track with starting or end line, digital imaging recomposition background.
JAK inhbitors are racing to the finish in atopic dermatitis. • Source: Shutterstock

Pfizer Inc. already is a leader in Janus kinase (JAK) inhibition with its blockbuster Xeljanz (tofacitinib) in various indications, but the company's first set of Phase III data for its second JAK-targeting drug abrocitinib keep it near the lead in the race to get a JAK inhibitor approved in atopic dermatitis (AD).

Eli Lilly & Co. may have a leg up on Pfizer after reporting positive top-line results from two out of five Phase III atopic dermatitis trials for its JAK1/2 inhibitor Olumiant (baricitinib) in February

More from Clinical Trials

More from R&D

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.